News
10-02-2013, 05:00 AM
The U.S. Food and Drug Administration granted accelerated approval of a Perjeta- (pertuzumab) regimen for neoadjuvant treatment (use before surgery) in people with high-risk, HER2-positive early stage breast cancer.
More... (http://www.news-medical.net/news/20131002/FDA-grants-accelerated-approval-of-Perjeta-for-people-with-HER2-positive-early-stage-breast-cancer.aspx)
More... (http://www.news-medical.net/news/20131002/FDA-grants-accelerated-approval-of-Perjeta-for-people-with-HER2-positive-early-stage-breast-cancer.aspx)